Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM), ISIN INE048B01035 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
JAGSNPHARM last traded at ₹225.90 (-0.02%), with a 52-week range of ₹154.90 to ₹264.65 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 69.05%, FIIs 2.30%, DIIs 0.62%, mutual funds 0.00%.
EquiSense Score (ECS): 78/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.